Single User License
INR 136060
Site License
INR 272120
Corporate User License
INR 408180

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Periodontitis-Pipeline Review, H2 2016

Periodontitis-Pipeline Review, H2 2016


  Request for Sample Report

Executive Summary

Periodontitis-Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Periodontitis-Pipeline Review, H2 2016', provides an overview of the Periodontitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Periodontitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Periodontitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Periodontitis

The report reviews pipeline therapeutics for Periodontitis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Periodontitis therapeutics and enlists all their major and minor projects

The report assesses Periodontitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Periodontitis

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Periodontitis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Periodontitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Periodontitis Overview 8

Therapeutics Development 9

Pipeline Products for Periodontitis-Overview 9

Pipeline Products for Periodontitis-Comparative Analysis 10

Periodontitis-Therapeutics under Development by Companies 11

Periodontitis-Therapeutics under Investigation by Universities/Institutes 12

Periodontitis-Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Unknown Stage Products 16

Periodontitis-Products under Development by Companies 17

Periodontitis-Products under Investigation by Universities/Institutes 18

Periodontitis-Companies Involved in Therapeutics Development 19

Amyndas Pharmaceuticals LLC 19

C3 Jian, Inc 20

CSL Limited 21

Ensol Biosciences Inc. 22

Enzo Biochem, Inc. 23

Geistlich Pharma AG 24

Kaken Pharmaceutical Co., Ltd. 25

TGV-Laboratories 26

Periodontitis-Therapeutics Assessment 27

Assessment by Monotherapy Products 27

Assessment by Target 28

Assessment by Mechanism of Action 30

Assessment by Route of Administration 32

Assessment by Molecule Type 34

Drug Profiles 36

AMY-101-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Drug to Antagonize C5aR for Periodontitis-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Enzo-D58-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

GM-0111-Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Hesed-3000-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Mul-1867-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

PODCRC-OHS-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

R-10001-Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Recombinant Protein to Activate Del-1 for Multiple Sclerosis and Periodontitis-Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Small Molecule to Inhibit MMP and Cytokine for Immunology, Respiratory and Musculoskeletal Disorders-Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Small Molecules for Periodontitis-Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

ST-266-Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Synthetic Peptides for Periodontitis-Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

taurolidine-Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

trafermin-Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

Periodontitis-Dormant Projects 53

Periodontitis-Discontinued Products 54

Periodontitis-Product Development Milestones 55

Featured News & Press Releases 55

Jun 15, 2016: Noveome Initiates Phase 2 Clinical Trial of ST266 to Treat Patients with Periodontitis 55

Mar 07, 2016: Penn Team Reverses Signs of Naturally Occurring Chronic Periodontitis 55

Oct 01, 2015: Kaken Submits a New Drug Application for "KCB-1D", Medicinal Product for Periodontal Regeneration 57

May 20, 2014: Penn Team Identifies Promising New Target for Gum Disease Treatment 57

Mar 30, 2012: Kaken Pharma To Initiate Additional Phase III Trial For KCB-1D 58

Oct 21, 2004: Kaken Pharmaceutical Announces Results Of Early Phase II Clinical Trial On KCB-1D 58

Appendix 59

Methodology 59

Coverage 59

Secondary Research 59

Primary Research 59

Expert Panel Validation 59

Contact Us 59

Disclaimer 60

List of Figures

Number of Products under Development for Periodontitis, H2 2016 9

Number of Products under Development for Periodontitis-Comparative Analysis, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Number of Products under Investigation by Universities/Institutes, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 14

Comparative Analysis by Early Stage Products, H2 2016 15

Assessment by Monotherapy Products, H2 2016 27

Number of Products by Targets, H2 2016 28

Number of Products by Stage and Targets, H2 2016 28

Number of Products by Mechanism of Actions, H2 2016 30

Number of Products by Stage and Mechanism of Actions, H2 2016 30

Number of Products by Routes of Administration, H2 2016 32

Number of Products by Stage and Routes of Administration, H2 2016 32

Number of Products by Molecule Types, H2 2016 34

Number of Products by Stage and Molecule Types, H2 2016 34

List of Tables

Number of Products under Development for Periodontitis, H2 2016 9

Number of Products under Development for Periodontitis-Comparative Analysis, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Number of Products under Investigation by Universities/Institutes, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Clinical Stage Development, H2 2016 14

Comparative Analysis by Early Stage Development, H2 2016 15

Comparative Analysis by Unknown Stage Development, H2 2016 16

Products under Development by Companies, H2 2016 17

Products under Investigation by Universities/Institutes, H2 2016 18

Periodontitis-Pipeline by Amyndas Pharmaceuticals LLC, H2 2016 19

Periodontitis-Pipeline by C3 Jian, Inc, H2 2016 20

Periodontitis-Pipeline by CSL Limited, H2 2016 21

Periodontitis-Pipeline by Ensol Biosciences Inc., H2 2016 22

Periodontitis-Pipeline by Enzo Biochem, Inc., H2 2016 23

Periodontitis-Pipeline by Geistlich Pharma AG, H2 2016 24

Periodontitis-Pipeline by Kaken Pharmaceutical Co., Ltd., H2 2016 25

Periodontitis-Pipeline by TGV-Laboratories, H2 2016 26

Assessment by Monotherapy Products, H2 2016 27

Number of Products by Stage and Target, H2 2016 29

Number of Products by Stage and Mechanism of Action, H2 2016 31

Number of Products by Stage and Route of Administration, H2 2016 33

Number of Products by Stage and Molecule Type, H2 2016 35

Periodontitis-Dormant Projects, H2 2016 53

Periodontitis-Discontinued Products, H2 2016 54

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Amyndas Pharmaceuticals LLC

C3 Jian, Inc

CSL Limited

Ensol Biosciences Inc.

Enzo Biochem, Inc.

Geistlich Pharma AG

Kaken Pharmaceutical Co., Ltd.

TGV-Laboratories

Periodontitis Therapeutic Products under Development, Key Players in Periodontitis Therapeutics, Periodontitis Pipeline Overview, Periodontitis Pipeline, Periodontitis Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com